FDA Approval of PerQseal Elite Strengthens Haemonetics' Hospital Closure Portfolio

What happened

Haemonetics received FDA approval for PerQseal Elite, a large-bore arterial vascular closure system, expanding its Hospital segment into structural heart and endovascular procedures. This follows the January 2026 acquisition of Vivasure Medical and adds a differentiated product to a portfolio that already benefits from electrophysiology and PFA-driven procedure growth. The approval aligns with management's strategy to prioritize Hospital growth, which has been a bright spot amid Plasma segment headwinds from the CSL Plasma transition. While the news is positive for the Hospital franchise, revenue contribution will depend on commercial execution and competitive dynamics in the large-bore closure market, where established players like Abbott and others compete. The Plasma segment remains a near-term drag, and the overall investment thesis remains balanced between Hospital momentum and Plasma stabilization.

Implication

The approval expands Haemonetics' addressable market in large-bore arterial closure, complementing existing venous closure products and reinforcing the Hospital segment's growth potential. However, the company must still navigate the CSL Plasma disposables exit in fiscal 2026, which is expected to pressure overall revenues and margins. The stock's discounted valuation relative to device peers likely reflects this Plasma uncertainty, and a successful Hospital ramp could support multiple expansion over time. Investors should monitor adoption metrics for PerQseal Elite, as competitive responses and hospital purchasing cycles could slow uptake. Maintain a watchful stance until evidence of Plasma stabilization and sustained Hospital outperformance emerges, consistent with the prior DeepValue judgment.

Thesis delta

The FDA approval is a positive development that strengthens the Hospital segment's competitive position and expands its product portfolio into large-bore arterial closure. This modestly improves the growth outlook for the Hospital franchise, which is a key offset to Plasma weakness. However, the overall thesis remains 'Watch/Neutral' because the near-term earnings impact is uncertain and Plasma headwinds persist.